行情

RGNX

RGNX

Regenxbio
NASDAQ

实时行情|Nasdaq Last Sale

38.39
+0.69
+1.83%
盘后: 38.16 -0.23 -0.60% 16:11 10/16 EDT
开盘
37.82
昨收
37.70
最高
38.92
最低
36.77
成交量
39.84万
成交额
--
52周最高
73.81
52周最低
30.38
市值
14.13亿
市盈率(TTM)
-27.8108
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RGNX 新闻

  • 爱立信第三季度营业利润超预期
  • 新浪财经.36分钟前
  • 意大利内阁批准2020财年预算草案 修法打击偷漏税
  • 中国新闻网.2小时前
  • 韩国访日游客连续两个月大减
  • 新浪财经综合.2小时前
  • 欧盟峰会即将举行 英国“脱欧”还是“拖欧”?
  • 央视.2小时前

更多

所属板块

生物技术和医学研究
-0.12%
制药与医学研究
0.00%

热门股票

名称
价格
涨跌幅

RGNX 简况

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
展开

Webull提供Regenxbio Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。